Arbutus Biopharma Corp (ABUS) — SEC Filings

Latest SEC filings for Arbutus Biopharma Corp (ABUS), explained in plain English.

Sentiment Overview: 1 bearish, 45 neutral, 1 mixed

Recent Filings (47)

• 8-K Filing — 8-K · 2025-12-11T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-13T00:00:00.000Z [neutral]
• Arbutus Narrows Losses by 48% on Soaring Revenue, Cost Cuts — 10-Q · 2025-11-13T00:00:00.000Z [mixed] Risk: medium
  Arbutus Biopharma Corp (ABUS) reported a significant reduction in net loss for the nine months ended September 30, 2025, decreasing to $29.7 million from $57.4
• Arbutus Biopharma Files 8-K — 8-K · 2025-10-07T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on October 7, 2025, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceu
• Arbutus Biopharma Corp. Files 8-K — 8-K · 2025-09-10T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corp. filed an 8-K on September 10, 2025, reporting on other events and financial statements. The filing indicates a change in the company's p
• Arbutus Biopharma Files 8-K on Operations and Personnel — 8-K · 2025-08-06T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on August 6, 2025, reporting on events as of August 4, 2025. The filing covers results of operations and financial co
• Arbutus Biopharma Q2 Loss Widens Amid Rising R&D Costs — 10-Q · 2025-08-06T00:00:00.000Z [bearish] Risk: high
  Arbutus Biopharma Corp reported a net loss of $25.2 million for the three months ended June 30, 2025, a significant increase from the net loss of $19.8 million
• Arbutus Biopharma Terminates Material Definitive Agreement — 8-K · 2025-06-25T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. announced on June 20, 2025, the termination of a material definitive agreement. The company, formerly known as Tekmira Pharmaceuticals C
• Arbutus Biopharma Files 8-K on Shareholder Vote Matters — 8-K · 2025-05-23T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corp. filed an 8-K on May 23, 2025, reporting on matters submitted to a vote of security holders as of May 21, 2025. The filing indicates a ch
• Arbutus Biopharma Files 8-K on Operations and Financials — 8-K · 2025-05-14T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
• 10-Q Filing — 10-Q · 2025-05-14T00:00:00.000Z [neutral]
• Arbutus Biopharma Files 8-K — 8-K · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on May 7, 2025, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceutica
• Arbutus Biopharma Files 8-K — 8-K · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on April 23, 2025, reporting on other events and financial statements. The company, formerly known as Tekmira Pharmac
• Arbutus Biopharma Files Definitive Proxy Statement — DEF 14A · 2025-04-04T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corp filed a Definitive Proxy Statement (DEF 14A) on April 4, 2025, for its annual meeting on May 21, 2025. The filing concerns the solicitati
• Arbutus Biopharma Corp. Announces Board and Executive Changes — 8-K · 2025-04-03T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. announced on March 28, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported th
• Arbutus Biopharma Files 8-K on Financials — 8-K · 2025-03-27T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing also includes financial
• Arbutus Biopharma Files 2024 10-K — 10-K · 2025-03-27T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp filed its 2024 10-K on March 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Tekmira Phar
• Arbutus Biopharma Corp Files 8-K Report — 8-K · 2025-03-03T00:00:00.000Z [neutral] Risk: medium
  On March 3, 2025, Arbutus Biopharma Corporation filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financi
• Arbutus Biopharma Corp Files 8-K on Director/Officer Changes — 8-K · 2025-02-25T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on February 25, 2025, reporting on the departure of a director, the election of new directors, and the appointment of
• Arbutus Biopharma Files 8-K — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on January 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also i
• Arbutus Biopharma Files 8-K — 8-K · 2024-11-15T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corp. filed an 8-K on November 15, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceutica
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Arbutus Biopharma Files 8-K — 8-K · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on November 6, 2024, reporting on its results of operations, financial condition, and other events. The filing includ
• Arbutus Biopharma Reports Q3 2024 Results — 10-Q · 2024-11-06T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. reported its financial results for the quarter ended September 30, 2024. The company's revenue from collaboration and contracts for the
• Arbutus Biopharma Files 8-K — 8-K · 2024-10-15T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on October 15, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmace
• Arbutus Biopharma Reports Director Changes and Compensation — 8-K · 2024-10-11T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. filed an 8-K on October 11, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also i
• Arbutus Biopharma Files Q2 2024 10-Q — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. filed a 10-Q for the period ending June 30, 2024. The company, formerly Tekmira Pharmaceuticals Corp., reported financial results for th
• Arbutus Biopharma Files 8-K for Regulation FD Disclosure — 8-K · 2024-08-05T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corp. filed an 8-K on August 5, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of t
• Arbutus Biopharma Files 8-K with Operational Updates — 8-K · 2024-08-01T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on August 1, 2024, reporting on results of operations, other events, and financial statements. The filing also notes
• SC 13G Filing — SC 13G · 2024-06-10T00:00:00.000Z [neutral]
• Arbutus Biopharma Files 8-K, Changes Address — 8-K · 2024-06-06T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on June 6, 2024, to report other events and financial statements. The filing indicates a change in the company's prin
• Arbutus Biopharma Files 8-K — 8-K · 2024-06-05T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on June 5, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceutic
• Arbutus Biopharma Corp. Announces Board and Executive Changes — 8-K · 2024-05-28T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. announced on May 22, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure o
• Arbutus Biopharma Corp Files 8-K — 8-K · 2024-05-22T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on May 22, 2024, reporting other events and financial statements. The filing also notes the company's former name was
• Whitefort Capital Amends Arbutus Biopharma Stake — SC 13D/A · 2024-05-17T00:00:00.000Z [neutral] Risk: medium
  Whitefort Capital Management, LP has amended its Schedule 13D filing regarding Arbutus Biopharma Corporation, as of May 17, 2024. The filing indicates a change
• Whitefort Capital Files 13D on Arbutus Biopharma — SC 13D · 2024-05-09T00:00:00.000Z [neutral] Risk: medium
  Whitefort Capital Management, LP has filed a Schedule 13D on May 9, 2024, indicating a change in beneficial ownership of Arbutus Biopharma Corporation. The fili
• Arbutus Biopharma Appoints New CEO, Dr. Sofia — 8-K · 2024-05-02T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corporation announced on May 1, 2024, a change in its board of directors. Specifically, Dr. Michael J. Sofia has been appointed as the new Chi
• Arbutus Biopharma Q1 2024 Update — 10-Q · 2024-05-02T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. reported its first quarter 2024 results, ending March 31, 2024. The company's financial statements indicate a period of operational acti
• Arbutus Biopharma Files Definitive Proxy Statement — DEF 14A · 2024-04-10T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corp. filed its definitive proxy statement on April 10, 2024, for its annual meeting on May 22, 2024. The company, formerly known as Tekmira P
• Arbutus Biopharma Files 8-K — 8-K · 2024-04-04T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on April 4, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceuti
• Arbutus Biopharma Files 2023 10-K — 10-K · 2024-03-05T00:00:00.000Z [neutral] Risk: medium
  Arbutus Biopharma Corp. filed its 2023 10-K on March 5, 2024, reporting on its fiscal year ending December 31, 2023. The company, formerly known as Tekmira Phar
• Arbutus Biopharma Files 8-K on Financial Condition — 8-K · 2024-02-29T00:00:00.000Z [neutral] Risk: low
  Arbutus Biopharma Corporation filed an 8-K on February 29, 2024, reporting on its financial condition and other events. The company, incorporated in British Col
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• BlackRock Amends Arbutus Biopharma Stake, Maintains Passive Position — SC 13G/A · 2024-02-12T00:00:00.000Z [neutral] Risk: low
  BlackRock Inc. filed an amended SC 13G/A on February 12, 2024, indicating its ownership of Arbutus Biopharma Corp's Common Stock as of December 31, 2023. This f
• Arbutus Biopharma Confirms Nasdaq Listing for ABUS Common Shares — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Arbutus Biopharma Corporation filed an 8-K on January 8, 2024, to report on its current status, including its registration of Common Shares, without par value,
• Arbutus Biopharma Reports Executive Changes, Compensation on Dec 31 — 8-K · 2024-01-04T00:00:00.000Z [neutral]
  Arbutus Biopharma Corp filed an 8-K on January 4, 2024, reporting an event on December 31, 2023, related to changes in directors or officers and their compensat